June 08, 2021
1 min read
Published by:
Nichols KK. Real world effectiveness of lifitegrast in dry eye disease patients across clinical practices in the United States and Canada. Presented at: Association for Research in Vision and Ophthalmology (virtual meeting); May 1-7, 2021.
Disclosures: Nichols reports she is a consultant to Allergan, Bruder, Kala, Oyster Point, Pentavision, ScienceBased Health, Shire/Novartis, Sight Sciences, TearFilm Innovations/Alcon/Acquiom and TopiVert; and reports research support from Alcon, Kala, NIH NEI, TearScience and Tear Solutions.
Data presented at the virtual Association for Research in Vision and Ophthalmology meeting showed that subjects dosed with Xiidra experienced improvement in dry eye disease and symptoms over 12 months.
According to Kelly K. Nichols, OD, MPH, PhD, FAAO, who presented the data in a poster, previous randomized control trials demonstrated the safety and efficacy of Xiidra (lifitegrast, Novartis) in treating dry eye disease; however, data from real-world patient experiences were limited.
Nichols and colleagues evaluated charts from 600 patients with dry eye who received treatment with lifitegrast. Most of the patients were women, and 27.8% reported contact lens use. More than 62% of patients had evaporative dry eye disease, according to the recruiting eye care professional.
More than 90% of patients were followed for at least 6 months, and more than 45% were followed for at least 12 months, with 12.7% of patients discontinuing treatment during the study period.
Compared with baseline, patients had improved tear film break-up time (4 vs. 8 seconds) and corneal staining score (2 vs. 4) at both 6 and 12 months.
Additionally, the rates of dry eye symptoms decreased from baseline compared with the 6- and 12-month follow-ups, including eye dryness (87% vs. 7% to 5%), blurred vision (58% vs. 5% to 3%), ocular blurring or stinging (56% vs. 3% to 2%), foreign body sensation (50% vs. 2%) and ocular pain (12% vs 1%).
Of the 281 patients with 12 months of follow-up, 84.7% were still being treated with lifitegrast.
“Based on ECP recruitment process, the sample is representative of a broad spectrum of clinical practice,” Nichols and colleagues wrote in their conclusion. “A high proportion of patients reported using lifitegrast alone post-index, potentially lessening their burden of treatment after introduction of lifitegrast.”
Read more about
Vision Expo East
June 09, 2021 at 02:23AM
https://www.healio.com/news/optometry/20210608/longterm-realworld-data-shows-xiidra-effective-against-dry-eye
Long-term, real-world data shows Xiidra effective against dry eye - Healio
https://news.google.com/search?q=dry&hl=en-US&gl=US&ceid=US:en
No comments:
Post a Comment